Eventide Asset Management, LLC Neurocrine Biosciences Inc Transaction History

Eventide Asset Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$106.72 - $127.06 $10.7 Million - $12.7 Million	-100,000 Reduced 42.55%	135,000 $16.1 Million
Q2 2021 Aug 16, 2021	SELL	$89.43 - $102.27 $21.4 Million - $24.4 Million	-239,000 Reduced 50.42%	235,000 $22.9 Million
Q1 2021 May 14, 2021	BUY	$87.57 - $119.4 $10.6 Million - $14.4 Million	121,000 Added 34.28%	474,000 $46.1 Million
Q4 2020 Feb 16, 2021	SELL	$86.91 - $108.33 $625,752 - $779,976	-7,200 Reduced 2.0%	353,000 $33.8 Million
Q3 2020 Nov 13, 2020	BUY	$96.16 - $135.15 $230,784 - $324,360	2,400 Added 0.67%	360,200 $34.6 Million
Q2 2020 Aug 14, 2020	BUY	$85.09 - $130.36 $408,432 - $625,728	4,800 Added 1.36%	357,800 $43.7 Million
Q2 2019 Aug 14, 2019	BUY	$72.24 - $91.27 $6 Million - $7.58 Million	83,000 Added 30.74%	353,000 $29.8 Million
Q1 2019 May 15, 2019	BUY	$69.31 - $91.53 $7.9 Million - $10.4 Million	114,000 Added 73.08%	270,000 $23.8 Million
Q4 2017 Feb 14, 2018	BUY	$58.53 - $77.59 $1.81 Million - $2.41 Million	31,000 Added 24.8%	156,000 $12.1 Million
Q3 2017 Nov 14, 2017	BUY	$47.97 - $61.28 $6 Million - $7.66 Million	125,000	125,000 $7.66 Million

635

93.5M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $14.1B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Eventide Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Eventide Asset Management, LLC with notifications on news.